Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Directed evolution of genetically encoded LYTACs for cell-mediated delivery

21 Mar 2024

Abstract excerpt

Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. However, early versions of LYTAC contain synthetic glycopeptides that cannot be genetically encoded. Here, we present our designs for a fully genetically encodable LYTAC (GELYTAC), making our tool compatible with integration into therapeutic cells for targeted delivery at diseased sites....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to RNA Interference and Gene Delivery
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38513100
DOI: 10.1073/pnas.2320053121

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Directed evolution of genetically encoded LYTACs for cell-mediated deliveryPMID 38513100Read ↗

Directed Evolution of Genetically Encoded LYTACs for Cell-Mediated DeliverySemantic proximity Read ↗

AAV delivered lysosome-targeting chimeras mediate sustained antibody depletion <i>in vivo</i>Semantic proximity Read ↗

Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting ReceptorsSemantic proximity Read ↗

TROP2-targeting chimeras (TRTACs) for tumor-selective membrane protein degradation and enhanced drug deliverySemantic proximity Read ↗

Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination TherapySemantic proximity Read ↗

Bioengineering multifunctional extracellular vesicles for targeted delivery of biologics to T cellsSemantic proximity Read ↗

Engineering of extracellular vesicles for display of protein biotherapeuticsSemantic proximity Read ↗

A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapySemantic proximity Read ↗

Degron-based bioPROTACs for controlling signaling in CAR T cellsSemantic proximity Read ↗

Engineering Memory T Cells as a platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage DisordersSemantic proximity Read ↗

<i>In Vivo</i> Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem CellsSemantic proximity Read ↗

VesicleVoyager: In vivo selection of surface displayed proteins that direct extracellular vesicles to tissue-specific targetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.